Xbrane Biopharma is Biotechnology in Sweden that focus on Xbrane Biopharma AB business. Founded in 2008. They cover business area such as Xbrane Biopharma AB, biosimilar, generic long-act injectable, product, Spherotide, prostate cancer, breast cancer, endometriosis, myoma, Xlucane, age-relate macular degeneration, diabetes-relate macular edema, diabetic retinopathy, retinal vein occlusion, two segment, Biosimilars and Long-act Injectables, Administration.
2008
( 16 years old in 2024 )
Xbrane Biopharma AB
-
Retzius Väg 8
171 48 Solna
Sweden
Private
Xbrane Biopharma ABbiosimilargeneric long-act injectableproductSpherotideprostate cancerbreast cancerendometriosismyomaXlucaneage-relate macular degenerationdiabetes-relate macular edema, diabetic retinopathyretinal vein occlusiontwo segmentBiosimilars and Long-act InjectablesAdministration
* We use standard office opening hours in near Xbrane Biopharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Xbrane Biopharma is Biotechnology business from Sweden that founded in 2008 (16 years old in 2024), Xbrane Biopharma business is focusing on Xbrane Biopharma AB.
Xbrane Biopharma headquarter office and corporate office address is located in Retzius Väg 8 171 48 Solna Sweden.
Xbrane Biopharma was founded in Sweden.
In 2024, Xbrane Biopharma is currently focus on Xbrane Biopharma AB sector.
Above is snippet of Google Trends for "Xbrane Biopharma AB" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Xbrane Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
